The global rapid acting insulin market was valued at $7,100 million in 2019, and is projected to reach $8,925 million by 2027 at a CAGR of 4.1% from 2020 to 2027. The growth of the global rapid acting ...

Tandem Diabetes Care, Inc. TNDM announced that the in-warranty users of the t:slim X2 insulin pump in Canada can now access full compatibility with both Dexcom’s DXCM G7 and G6 Continuous Glucose ...

Sanofi’s Admelog (insulin lispro) is approved in type 1 and type 2 diabetes as a follow-on drug to Humalog, a rapid-acting insulin that is Lilly’s top selling drug, bringing in almost $700 ...

In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Ultra-Rapid Lispro (URLi) is a fast-acting insulin injection developed by Eli Lilly ...

THDB0206: Tonghua Dongbao Pharmaceutical BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the treatment of type 2 diabetes.

The present patient, who had diabetic nephropathy and retinopathy as secondary complications, was prescribed intensification therapy of subcutaneous injection of insulin (ultra-rapid-acting ...

In this instalment of our renewed clinical trials round-ups, we look at life sciences research and development announced during the week of 20th to 24th May, from early-stage onwards. During this ...

Efsitora is in phase III development for adults with type 1 and 2 diabetes. BC Lispro (THDB0206) is an ultra-rapid-acting insulin analog developed by Tonghua Dongbao Pharmaceutical Co., Ltd. for the ...

What is undoubtedly a first is that the supermarket will fully own and manage the charging network end-to-end and focus on ultra-rapid charging exclusively. Hardware and technology to do this come ...